Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. cut its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 42.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 19,247 shares of the biopharmaceutical company’s stock after selling 14,199 shares during the period. Fox Run Management L.L.C.’s holdings in Vanda Pharmaceuticals were worth $92,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in VNDA. Intech Investment Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the third quarter worth about $84,000. SG Americas Securities LLC boosted its holdings in Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 5,459 shares during the last quarter. Verition Fund Management LLC increased its stake in Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 2,927 shares in the last quarter. Franklin Resources Inc. increased its stake in Vanda Pharmaceuticals by 8.8% during the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 4,449 shares in the last quarter. Finally, ClearAlpha Technologies LP raised its holdings in shares of Vanda Pharmaceuticals by 50.0% during the third quarter. ClearAlpha Technologies LP now owns 60,000 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 20,000 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were purchased at an average cost of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the acquisition, the chief executive officer now owns 2,331,730 shares of the company’s stock, valued at approximately $10,399,515.80. The trade was a 0.43 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders have bought 32,000 shares of company stock valued at $151,180. 8.90% of the stock is currently owned by insiders.

Vanda Pharmaceuticals Trading Up 2.0 %

VNDA stock opened at $4.69 on Friday. The firm has a 50-day moving average of $4.66 and a two-hundred day moving average of $4.75. Vanda Pharmaceuticals Inc. has a 12 month low of $3.87 and a 12 month high of $6.75. The company has a market cap of $273.50 million, a price-to-earnings ratio of -14.66 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, equities analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on VNDA shares. HC Wainwright lifted their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.